Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
275 questions in 51 reviews · Stroke
current versionsNo studies 275 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Platelet transfusion vs open control Quality of life ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platelet transfusion vs open control Mood ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platelet transfusion vs open control Cognitive function ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma Quality of life ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma Mood ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma Cognitive function ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control Quality of life ‐ not reported · adults with acute spontaneous intracerebral haemorrhage Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control Mood ‐ not reported · adults with acute spontaneous intracerebral haemorrhage Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control Cognitive function ‐ not reported · adults with acute spontaneous intracerebral haemorrhage Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Cerebrolysin or Cerebrolysin‐like agents vs placebo Death or dependence, · people with acute ischaemic stroke Cerebrolysin for acute ischaemic stroke (2023) · Cochrane | no estimate extracted | NR | No studies |
Cerebrolysin or Cerebrolysin‐like agents vs placebo Early death (within 2 weeks of stroke onset) · people with acute ischaemic stroke Cerebrolysin for acute ischaemic stroke (2023) · Cochrane | no estimate extracted | NR | No studies |
Cerebrolysin or Cerebrolysin‐like agents vs placebo Quality of life · people with acute ischaemic stroke Cerebrolysin for acute ischaemic stroke (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Deaths due to vascular events · people with stroke or transient ischaemic attack Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Disability due to vascular events · people with stroke or transient ischaemic attack Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Improvement in quality of life · people with stroke or transient ischaemic attack Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Starting short‐term prophylactic dose anticoagulation vs avoiding anticoagulation MACE ‐ not reported · survivors of stroke due to intracerebral haemorrhage Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Cilostazol vs aspirin All major occlusive vascular events ‐ not reported · adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of… Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Cilostazol vs aspirin Functional status ‐ not reported · adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of… Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Endovascular therapy plus conventional medical treatment vs conventional medical treatment alone Restenosis (≥ 50%) · people with symptomatic intracranial artery stenosis Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Endovascular therapy plus conventional medical treatment vs conventional medical treatment alone Health‐related quality of life · people with symptomatic intracranial artery stenosis Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Antiplatelet agent vs placebo Outcomes (measurement) · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Antihypertensive agent vs placebo Neurological impairment · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Antihypertensive agent vs placebo Major bleeding · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Antihypertensive agent vs placebo Adverse events · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Antihypertensive agent vs placebo Quality of life · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulant agent vs placebo Outcomes (measurement/time point) · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulant agent vs placebo Neurological impairment · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulant agent vs placebo Ipsilateral major or disabling stroke · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Antiplatelet agent vs placebo Neurological impairment · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulant agent vs placebo Stroke‐related mortality · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulant agent vs placebo Progression of carotid stenosis · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulant agent vs placebo Quality of life · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Lipid‐lowering agent vs placebo or no treatment Outcomes (measurement/time point) · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Lipid‐lowering agent vs placebo or no treatment Neurological impairment · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Lipid‐lowering agent vs placebo or no treatment Major bleeding · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Lipid‐lowering agent vs placebo or no treatment Progression of carotid stenosis · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Lipid‐lowering agent vs placebo or no treatment Quality of life · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Antiplatelet agent vs placebo Quality of life · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Antihypertensive agent vs placebo Outcomes (measurement/time point) · asymptomatic carotid stenosis Pharmacological interventions for asymptomatic carotid stenosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary objectives for HINTS subcomponents Head impulse, nystagmus, and test of skew examination for diagnosing central causes of acute vestibular… (2023) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Activities of daily living (primary outcome) · stroke survivors with hearing, smell, and taste perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Quality of life and participation ‐ mobility and navigation intervention for not Pusher Syndrome (Analysis 1.2) · stroke survivors with somatosensory perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Psychological and mental health · stroke survivors with somatosensory perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Perception · stroke survivors with somatosensory perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Adverse events · stroke survivors with somatosensory perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Activities of daily living (primary outcome) · stroke survivors with tactile perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Extended activities of daily living · stroke survivors with tactile perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Psychological and mental health · stroke survivors with tactile perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Activities of daily living (primary outcome) · stroke survivors with vision perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Extended activities of daily living · stroke survivors with hearing, smell, and taste perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |